Medically reviewed by: Nish Fayyaz - MPharm | University of Strathclyde

Role: Registered Pharmacist GPhC: 2225257

Last reviewed: 22 May 2026

When will the Wegovy pill be available in the UK?

The “Wegovy pill” is one of the most talked-about developments in weight loss treatment right now. But is a tablet version of Wegovy actually available in the UK — and how does it compare to existing options?

Currently, Wegovy is only available as a weekly injection. However, an oral version of semaglutide — the active ingredient in Wegovy — is being developed for weight loss and is being referred to as the “Wegovy pill”.

Wegovy in tablet form is designed to offer the same appetite-reducing and weight loss benefits as injectable GLP-1 medications, but in a once-daily pill instead of a weekly injection.

In this guide, we explain what the Wegovy pill is, when it may be available in the UK, the cost and how it compares to pre-existing tablet options like Rybelsus.

What is the Wegovy tablet?

The needle-free alternative to Wegovy injections, Wegovy in tablet form, is coming to the UK. The Wegovy pill, created by Novo Nordisk, comes in an oral tablet version and contains the active ingredient semaglutide, the same active ingredient used in injectable weight loss medications like Wegovy and Ozempic.

Semaglutide is a GLP-1 receptor agonist that represses appetite, increases satiety and slows gastric emptying to aid and enhance weight loss.

The oral Wegovy weight loss pill is a convenient alternative to subcutaneous Wegovy, because you swallow a tablet once daily and do not have to inject the medication.

How much will the Wegovy pill cost in the UK?

The official UK price of the Wegovy pill will not be confirmed until the MHRA approves the medication and Novo Nordisk publishes its UK list price.

However, US launch pricing and the current cost of Wegovy injections in the UK give us a reasonable steer on what to expect.

How much does the Wegovy pill cost in the US?

The Wegovy pill launched in the United States in January 2026 through Novo Nordisk’s NovoCare Pharmacy programme.

Self-pay pricing for the oral tablet has been reported from around $149–$299 per month depending on dose, significantly lower than the historical US list price of injectable Wegovy, which has exceeded $1,300 per month.

The reduced self-pay price was designed to make oral semaglutide more accessible to patients without insurance coverage.

How much could the Wegovy pill cost in the UK?

UK pricing rarely mirrors US pricing because the two healthcare systems use very different pricing and reimbursement models.

The more useful benchmark is the current UK private price of Wegovy injections, which typically starts from around £150 per month at the lowest dose and rises to over £250 per month at higher maintenance doses when purchased through regulated UK online pharmacies.

We expect the Wegovy pill to launch within a broadly similar private monthly cost range, with the exact price varying by dose and supplying pharmacy.

Will the Wegovy pill be available on the NHS?

Wegovy injections are currently available on the NHS only through specialist tier 3 weight management services, with strict eligibility criteria.

The Wegovy pill is likely to follow a similar pathway: NICE will need to assess its cost-effectiveness before recommending it for NHS use, and even then, access is likely to remain limited to specialist services rather than routine GP prescribing.

For most patients in the UK, the pill will be accessed privately through regulated online pharmacies like Pharmacy Online once it launches.

When will the Wegovy Pill be available in the UK?

As of time of writing, the Wegovy pill is still currently in the process of approval with the Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE). Therefore, the exact timeline for UK availability remains uncertain.

However, MHRA-approval of the Wegovy oral tablet is expected by many in the industry to be imminent, and here at Pharmacy Online, we are expecting the pill to be available by summer, 2026.

How weight loss medication approval works in the UK

Before medicines such as the Wegovy pill can be prescribed in the UK, they must first be assessed by the MHRA. The MHRA is responsible for ensuring medicines meet strict standards for safety, quality and effectiveness before they can be licensed for market, sale and supply.

Following MHRA approval, NICE may then review the medication for NHS use in England. NICE assesses factors such as clinical effectiveness and cost-effectiveness before issuing guidance on NHS prescribing.

NICE guidelines do not automatically apply to Scotland; it is the Scottish Medicines Consortium (SMC) who decides which medicines are used.

Because of these review processes, new weight loss medications often become available through private clinics and online pharmacies like Pharmacy Online before wider NHS access is available.

Has the Novo Nordisk Wegovy Pill been approved elsewhere?

The Wegovy oral tablet was approved in the USA in December 2025 and launched to market by January 2026.

In the USA, it was reported that the Wegovy pill saw the fastest take-up in weight loss drug history (Goldstein, 2026).

Wegovy pill vs injection comparison

For anyone weighing up the oral tablet against the existing weekly injection, the most important differences come down to how each is taken, how often, how the maximum dose compares, and how reliably the body absorbs the active ingredient. The table below sets out the main practical and clinical differences side by side.

Will the tablet replace the injections?

The Wegovy oral tablet is unlikely to replace injections entirely as different patients have different preferences when it comes to taking weight loss medication.

Some patients will prefer to jab once per week over remembering to take a tablet every day, whereas others who were potentially put off by injections may now feel more comfortable taking the Wegovy pill.

Additionally, a new 2026 study showed oral GLP-1 pills may help people maintain weight loss after stopping injections (BMJ, 2026).

That could become a major future use for the tablets:

1. Lose weight on injections
2. Maintain on tablets long term

Wegovy pill vs other weight loss medications

To understand how the Wegovy pill fits into the wider weight loss medication landscape, it helps to compare it against other GLP-1 and incretin-based treatments that are either already available in the UK or moving through approval.

The table below brings together the headline weight loss figures from the major Phase 3 clinical trials for the leading oral and injectable options.

These results come from separate trials with different durations, eligibility criteria and dose schedules, so the figures should be read as a useful benchmark rather than a true head-to-head comparison.

What this comparison shows is that oral GLP-1 tablets like the Wegovy pill currently deliver slightly less weight loss on average than the latest injectable options, but they offer a needle-free, once-daily alternative that we know many patients will find easier to integrate into daily life.